PepGen reported 46.5% muscle correction and gains in movement tests, with no severe side effects or treatment stops. Patient-reported results were mixed, but the measured gains support its DM1 drug.
The findings suggest its drug may address DM1 muscle changes and movement problems. Only 6 patients received this dose, so larger groups must confirm the gains. Patient-reported results were mixed, but measured function improved and no severe side effects or treatment stops were reported.
Dyne is nearing completion of a pivotal trial, but this story gives no result from it. The progress is noted without evidence of how the drug performed, so this story does not change its outlook.
Novartis reported a Phase 3 failure for its acquired DM1 candidate, weakening prospects for that drug. The story gives no positive update on the candidate.
Follow PepGen Inc. (PEPG) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PEPG